Angiogenesis in cutaneous T‑cell lymphoma ‑ proteomic approaches (Review)
Open Access
- 19 November 2018
- journal article
- review article
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (5) , 4060-4067
Abstract
Neoangiogenesis plays an important role in cutaneous lymphoma pathogenesis. Cutaneous T‑cell lymphoma (CTCL) is characterized by the presence of malignant T‑cell clones in the skin. Vascular microenvironment of lymphomas accelerates neoangiogenesis through several factors released by tumoral cells: VEGF family, bFGF and PIGF. Tumor stroma (fibroblasts, inflammatory and immune cells) also plays a crucial role, by providing additional angiogenic factors. The angiogenic process through the VEGF‑VEGFR axis can promote survival, proliferation and metastasis via autocrine mechanisms in cutaneous lymphomas. Microvascular density (MVD) measures the neo‑vascularization of cutaneous lymphoma, generated by the response of tumor cells, proangiogenic stromal cells, and benign T/B lymphocytes within the tumor inflammatory infiltrate. Pro‑angiogenic proteins have been found to indicate the evolution and prognosis in patients with CTCL. In conclusion, anti‑angiogenic therapeutic protocols can target tumor vasculature or malignant tumor cells directly or through a large number of combinations with other drugs. The integration of proteomics into clinical practice based on high‑throughput technologies leads to the development of personalized medicine, adapting the specific biomarkers to the application of cancer‑type specific individual drug targets.Keywords
This publication has 85 references indexed in Scilit:
- Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and LimitationsBioMed Research International, 2013
- Novel therapeutic agents for cutaneous T-Cell lymphomaJournal of Hematology & Oncology, 2012
- Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) CellsPLOS ONE, 2011
- Proteome and cytokine serum profiling to diagnose a mycosis fungoidesProteomics – Clinical Applications, 2011
- Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesInvestigational New Drugs, 2010
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2010
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994